Literature DB >> 22822194

Prospective longitudinal study of thromboelastography and standard hemostatic laboratory tests in healthy women during normal pregnancy.

Ove Karlsson1, Tommy Sporrong, Andreas Hillarp, Anders Jeppsson, Margareta Hellgren.   

Abstract

BACKGROUND: Hemostatic disorders are common in obstetric complications. Thromboelastography (TEG®) simultaneously measures coagulation and fibrinolysis within 10 to 20 minutes. Our primary aim in this prospective longitudinal study was to obtain knowledge about physiological changes in TEG® variables during normal pregnancy and 8 weeks postpartum. The secondary aims were to compare TEG® variables during pregnancy with TEG® variables 8 weeks postpartum and gestational weeks 10 to 15 and to correlate TEG® variables to standard laboratory analyses.
METHODS: Blood samples were collected from 45 healthy pregnant women at gestational weeks 10 to 15, 20 to 22, 28 to 30, and 38 to 40, and at 8 weeks postpartum. The following TEG® analyses were performed: time until start of clotting (TEG®-R), time until 20-mm clot firmness (TEG®-K), angle of clotting (TEG®-Angle), maximum amplitude (TEG®-MA), and lysis after 30 minutes (TEG®-LY30). Activated partial thromboplastin time, prothrombin time, soluble fibrin, antithrombin, D-dimer, and platelet count were analyzed.
RESULTS: Compared to 8 weeks postpartum TEG®-R was at least 0.9 minutes shorter (upper limit 99% confidence intervals) until gestational weeks 28 to 30 and the mean reduction varied between 23%-26%. TEG®-K was at least 0.1 minutes shorter throughout pregnancy and the mean reduction varied between 18%-35%. TEG®-Angle was at least 2.5 degrees greater during pregnancy and the mean increase varied between 12%-20%. TEG®-MA was also at least 0.4 mm greater during pregnancy and the mean increase varied between 6%-8%. TEG®-LY30 was at least 0.03% lower during gestational weeks 28 to 30 and 38 to 40 and the mean reduction varied between 67%-73%. The routine coagulation laboratory values were within normal pregnant limits. There were no or weak correlations between TEG® and the laboratory variables.
CONCLUSIONS: TEG® demonstrates increased coagulability and decreased fibrinolysis during pregnancy. There was a faster initiation of hemostasis, with a minor increase in clot strength. Fibrinolysis decreased during late pregnancy. Alternative cutoff limits for TEG® variables may be required during pregnancy. Standard hemostatic laboratory tests were as expected during pregnancy. Future studies are needed to ascertain whether viscoelastic methods are preferable to standard hemostatic tests for the diagnosis of coagulopathy during obstetric hemorrhage.

Entities:  

Mesh:

Year:  2012        PMID: 22822194     DOI: 10.1213/ANE.0b013e3182652a33

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  10 in total

Review 1.  Transfusion and coagulation management in major obstetric hemorrhage.

Authors:  Alexander J Butwick; Lawrence T Goodnough
Journal:  Curr Opin Anaesthesiol       Date:  2015-06       Impact factor: 2.706

2.  Thrombin generation test as a marker for high risk venous thrombosis pregnancies.

Authors:  Bérangère S Joly; Bénédicte Sudrié-Arnaud; Virginie Barbay; Jeanne-Yvonne Borg; Véronique Le Cam Duchez
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

Review 3.  Risk stratification for pregnancy-associated venous thromboembolism: Potential role for global coagulation assays.

Authors:  David O'Keefe; Hui Yin Lim; Lisa Hui; Prahlad Ho
Journal:  Obstet Med       Date:  2021-08-05

Review 4.  Peripartum Haemorrhage: Haemostatic Aspects of the New German PPH Guideline.

Authors:  Heiko Lier; Christian von Heymann; Wolfgang Korte; Dietmar Schlembach
Journal:  Transfus Med Hemother       Date:  2017-11-15       Impact factor: 3.747

5.  Assays of different aspects of haemostasis - what do they measure?

Authors:  Nahreen Tynngård; Tomas L Lindahl; Sofia Ramström
Journal:  Thromb J       Date:  2015-02-05

6.  Peripartum Haemorrhage, Diagnosis and Therapy. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 015/063, March 2016).

Authors:  Dietmar Schlembach; Hanns Helmer; Wolfgang Henrich; Christian von Heymann; Franz Kainer; Wolfgang Korte; Maritta Kühnert; Heiko Lier; Holger Maul; Werner Rath; Susanne Steppat; Daniel Surbek; Jürgen Wacker
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-04-26       Impact factor: 2.915

7.  To Clot or Not: HELLP Syndrome and Disseminated Intravascular Coagulation in an Eclamptic Patient with Intrauterine Fetal Demise.

Authors:  Justin Walker; Anthony Bonavia
Journal:  Case Rep Anesthesiol       Date:  2020-07-07

Review 8.  Physiological and anatomical changes of pregnancy: Implications for anaesthesia.

Authors:  Pradeep Bhatia; Swati Chhabra
Journal:  Indian J Anaesth       Date:  2018-09

9.  A Successful Mother and Neonate Outcome for a Woman with Essential Thrombocytosis and FV Leiden Heterozygosity.

Authors:  Marianna Politou; Serena Valsami; Irontianta Gkorezi-Ntavela; Vasilios Telonis; Efrosyni Merkouri; Panagiotis Christopoulos
Journal:  Case Rep Obstet Gynecol       Date:  2016-03-31

10.  Establishment of the Normal Reference Range of Thrombelastogram among the Healthy Population and Pregnants in China.

Authors:  Rong Gui; Xueyuan Huang; Ming Zhou; Shujuan Ouyang; Yunfeng Fu; Hao Tang; Fengxia Liu; Rong Huang; Meng Gao; Hang Dong; Yongjun Wang
Journal:  Iran J Public Health       Date:  2019-05       Impact factor: 1.429

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.